BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30194449)

  • 1. Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome.
    Shmueli MD; Levy-Kanfo L; Haj E; Schoenfeld AR; Gazit E; Segal D
    Oncogene; 2019 Feb; 38(7):1038-1049. PubMed ID: 30194449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.
    Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR
    Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
    Moch H
    Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
    Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN
    Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
    Knauth K; Bex C; Jemth P; Buchberger A
    Oncogene; 2006 Jan; 25(3):370-7. PubMed ID: 16261165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer.
    Chakraborty AA
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):34-42. PubMed ID: 32209418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
    Nakamura E; Abreu-e-Lima P; Awakura Y; Inoue T; Kamoto T; Ogawa O; Kotani H; Manabe T; Zhang GJ; Kondo K; Nosé V; Kaelin WG
    Am J Pathol; 2006 Feb; 168(2):574-84. PubMed ID: 16436671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
    Zhou L; Yang H
    PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
    Kapitsinou PP; Haase VH
    Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
    Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
    J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
    Zhang YT; Chen N; Zeng H; Zhou Q
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
    [No Abstract]   [Full Text] [Related]  

  • 18. The von Hippel-Lindau protein forms fibrillar amyloid assemblies that are mitigated by the anti-amyloid molecule Purpurin.
    Kumar V; Kaushik V; Kumar S; Levkovich SA; Gupta P; Laor Bar-Yosef D; Gazit E; Segal D
    Biochem Biophys Res Commun; 2024 Jan; 690():149250. PubMed ID: 38039781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational and experimental characterization of dVHL establish a Drosophila model of VHL syndrome.
    Shmueli MD; Schnaider L; Herzog G; Gazit E; Segal D
    PLoS One; 2014; 9(10):e109864. PubMed ID: 25310726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.